156 related articles for article (PubMed ID: 38219970)
1. Drug-drug co-amorphous systems: An emerging formulation strategy for poorly water-soluble drugs.
Wang H; Zhao P; Ma R; Jia J; Fu Q
Drug Discov Today; 2024 Feb; 29(2):103883. PubMed ID: 38219970
[TBL] [Abstract][Full Text] [Related]
2. Nucleotides as new co-formers in co-amorphous systems: Enhanced dissolution rate, water solubility and physical stability.
Liu X; Shen L; Zhou L; Wu W; Liang G; Zhao Y; Wu W
Eur J Pharm Biopharm; 2024 Jul; 200():114333. PubMed ID: 38768766
[TBL] [Abstract][Full Text] [Related]
3. Refining stability and dissolution rate of amorphous drug formulations.
Grohganz H; Priemel PA; Löbmann K; Nielsen LH; Laitinen R; Mullertz A; Van den Mooter G; Rades T
Expert Opin Drug Deliv; 2014 Jun; 11(6):977-89. PubMed ID: 24754747
[TBL] [Abstract][Full Text] [Related]
4. Amino acids as co-amorphous stabilizers for poorly water soluble drugs--Part 1: preparation, stability and dissolution enhancement.
Löbmann K; Grohganz H; Laitinen R; Strachan C; Rades T
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):873-81. PubMed ID: 23537574
[TBL] [Abstract][Full Text] [Related]
5. Emerging trends in the stabilization of amorphous drugs.
Laitinen R; Löbmann K; Strachan CJ; Grohganz H; Rades T
Int J Pharm; 2013 Aug; 453(1):65-79. PubMed ID: 22569230
[TBL] [Abstract][Full Text] [Related]
6. Co-amorphous systems for the delivery of poorly water-soluble drugs: recent advances and an update.
Han J; Wei Y; Lu Y; Wang R; Zhang J; Gao Y; Qian S
Expert Opin Drug Deliv; 2020 Oct; 17(10):1411-1435. PubMed ID: 32683996
[TBL] [Abstract][Full Text] [Related]
7. Tannic acid as a co-former in co-amorphous systems: Enhancing their physical stability, solubility and dissolution behavior.
Fael H; Demirel AL
Int J Pharm; 2020 May; 581():119284. PubMed ID: 32243965
[TBL] [Abstract][Full Text] [Related]
8. Ternary Solid Dispersions: A Review of the Preparation, Characterization, Mechanism of Drug Release, and Physical Stability.
Budiman A; Lailasari E; Nurani NV; Yunita EN; Anastasya G; Aulia RN; Lestari IN; Subra L; Aulifa DL
Pharmaceutics; 2023 Aug; 15(8):. PubMed ID: 37631330
[TBL] [Abstract][Full Text] [Related]
9. A trade-off between solubility enhancement and physical stability upon simultaneous amorphization and nanonization of curcumin in comparison to amorphization alone.
Wong JJL; Yu H; Lim LM; Hadinoto K
Eur J Pharm Sci; 2018 Mar; 114():356-363. PubMed ID: 29309874
[TBL] [Abstract][Full Text] [Related]
10. Effects of polymer addition on the non-strongly interacting binary co-amorphous system carvedilol-tryptophan.
Wang Y; Grohganz H; Rades T
Int J Pharm; 2022 Apr; 617():121625. PubMed ID: 35259442
[TBL] [Abstract][Full Text] [Related]
11. Dissolution changes in drug-amino acid/biotin co-amorphous systems: Decreased/increased dissolution during storage without recrystallization.
Zou Z; Huang Q; Li X; Liu X; Yin L; Zhao Y; Liang G; Wu W
Eur J Pharm Sci; 2023 Sep; 188():106526. PubMed ID: 37442486
[TBL] [Abstract][Full Text] [Related]
12. Co amorphous systems: A product development perspective.
Chavan RB; Thipparaboina R; Kumar D; Shastri NR
Int J Pharm; 2016 Dec; 515(1-2):403-415. PubMed ID: 27771485
[TBL] [Abstract][Full Text] [Related]
13. Transformations between Co-Amorphous and Co-Crystal Systems and Their Influence on the Formation and Physical Stability of Co-Amorphous Systems.
Wu W; Wang Y; Löbmann K; Grohganz H; Rades T
Mol Pharm; 2019 Mar; 16(3):1294-1304. PubMed ID: 30624075
[TBL] [Abstract][Full Text] [Related]
14. Permeability of glibenclamide through a PAMPA membrane: The effect of co-amorphization.
Ruponen M; Visti M; Ojarinta R; Laitinen R
Eur J Pharm Biopharm; 2018 Aug; 129():247-256. PubMed ID: 29894814
[TBL] [Abstract][Full Text] [Related]
15. Co-amorphous Drug Delivery Systems: a Review of Physical Stability, In Vitro and In Vivo Performance.
Shi Q; Wang Y; Moinuddin SM; Feng X; Ahsan F
AAPS PharmSciTech; 2022 Sep; 23(7):259. PubMed ID: 36123515
[TBL] [Abstract][Full Text] [Related]
16. Recent Technologies for Amorphization of Poorly Water-Soluble Drugs.
Kim DH; Kim YW; Tin YY; Soe MT; Ko BH; Park SJ; Lee JW
Pharmaceutics; 2021 Aug; 13(8):. PubMed ID: 34452279
[TBL] [Abstract][Full Text] [Related]
17. Physical stabilization of low-molecular-weight amorphous drugs in the solid state: a material science approach.
Qi S; McAuley WJ; Yang Z; Tipduangta P
Ther Deliv; 2014 Jul; 5(7):817-41. PubMed ID: 25287388
[TBL] [Abstract][Full Text] [Related]
18. Preparation of an amorphous sodium furosemide salt improves solubility and dissolution rate and leads to a faster Tmax after oral dosing to rats.
Nielsen LH; Gordon S; Holm R; Selen A; Rades T; Müllertz A
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):942-51. PubMed ID: 24075980
[TBL] [Abstract][Full Text] [Related]
19. Mesoporous silica materials: From physico-chemical properties to enhanced dissolution of poorly water-soluble drugs.
Maleki A; Kettiger H; Schoubben A; Rosenholm JM; Ambrogi V; Hamidi M
J Control Release; 2017 Sep; 262():329-347. PubMed ID: 28778479
[TBL] [Abstract][Full Text] [Related]
20. Drug-polymer solubility and miscibility: Stability consideration and practical challenges in amorphous solid dispersion development.
Qian F; Huang J; Hussain MA
J Pharm Sci; 2010 Jul; 99(7):2941-7. PubMed ID: 20127825
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
